The potential pro-cognitive effects with intravenous subanesthetic ketamine in adults with treatment-resistant major depressive or bipolar disorders and suicidality

被引:13
|
作者
Zhou, Yanling [1 ,2 ]
Wang, Chengyu [1 ,2 ]
Lan, Xiaofeng [1 ,2 ]
Zheng, Wei [1 ,2 ]
Li, Hanqiu [1 ,2 ]
Chao, Ziyuan [1 ,2 ]
Wu, Kai [1 ,2 ,3 ]
McIntyre, Roger S. [4 ,5 ,6 ,7 ,8 ,9 ]
Ning, Yuping [1 ,2 ,10 ]
机构
[1] Guangzhou Med Univ, Guangzhou Huiai Hosp, Affiliated Brain Hosp, Guangzhou, Peoples R China
[2] Guangdong Engn Technol Res Ctr Translat Med Menta, Guangzhou, Peoples R China
[3] South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou, Peoples R China
[4] Canadian Rapid Treatment Ctr Excellence, Mississauga, ON, Canada
[5] Univ Hlth Network, Poul Hansen Depress Ctr, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
[6] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[7] Univ Toronto, Inst Med Sci, Toronto, ON, Canada
[8] Brain & Cognit Discovery Fdn, Toronto, ON, Canada
[9] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada
[10] Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Cognition; Ketamine; Depression; Treatment resistance; Suicidality; DOUBLE-BLIND; NEUROCOGNITIVE PERFORMANCE; FUNCTIONAL OUTCOMES; ANTIDEPRESSANT; EFFICACY; ASSOCIATION; ESKETAMINE; IMPAIRMENT;
D O I
10.1016/j.jpsychires.2021.10.037
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Ketamine has rapid and robust antidepressant effects in depression, while its effects on cognitive measures are less clearly understood. This aim of the study herein is to determine whether ketamine has direct pro-cognitive effects in real-world treatment depression and/or suicidality. Methods: Subjects with unipolar (n = 84) and bipolar (n = 27) depression suffering treatment resistance or suicidality received six infusions of ketamine (0.5 mg/kg) during a 12-day period. Depression symptoms were assessed using the Montgomery-Asberg Depression Rating Scale at baseline, day 13 and day 26. Cognitive domains, including processing speed, working memory, visual learning and verbal learning were also measured using the MATRICS Consensus Cognitive Battery at the same time-points. Results: Significant improvement was observed in processing speed at day 13 (effect size [ES] = 0.501) and day 26 (ES = 0.654), and verbal learning at day 13 (ES = 0.362). Path analysis showed significant direct (beta = 2.444, P = 0.017) and indirect (beta = 1.220, P = 0.048) effect of ketamine on processing speed, indicating its improvement was partly independent of improvement in depressive symptoms. The direct effect (beta = 1.963, P = 0.052) of ketamine on verbal learning was not significant, whereas the indirect effect (beta = 1.386, P = 0.024) was significant, indicating treatment with ketamine indirectly improved verbal learning performance, via changes in depressive symptom. Conclusion: Six infusions of ketamine have a potential mood independent pro-cognitive effect on processing speed in adults with treatment depression and/or suicidality. The potential pro-cognitive effects of ketamine provide the basis for hypothesizing that other clinical outcomes (e.g., suicidality, functional impairment) reported with ketamine treatment may be in part mediated by improvement in cognition.
引用
收藏
页码:312 / 319
页数:8
相关论文
共 50 条
  • [31] KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE
    Bobo, William V.
    Vande Voort, Jennifer L.
    Croarkin, Paul E.
    Leung, Jonathan G.
    Tye, Susannah J.
    Frye, Mark A.
    [J]. DEPRESSION AND ANXIETY, 2016, 33 (08) : 698 - 710
  • [32] Working-Memory Changes at Baseline and Following a Subanesthetic Dose of Intravenous Ketamine in Treatment-Resistant Depression Patients and Healthy Volunteers
    Fijtman, Adam
    Lally, Niall
    Greenstein, Dede
    Evans, Jennifer
    Zarate, Carlos
    [J]. BIOLOGICAL PSYCHIATRY, 2024, 95 (10) : S202 - S203
  • [33] Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response
    James W. Murrough
    Le-Ben Wan
    Brian Iacoviello
    Katherine A. Collins
    Carly Solon
    Benjamin Glicksberg
    Andrew M. Perez
    Sanjay J. Mathew
    Dennis S. Charney
    Dan V. Iosifescu
    Katherine E. Burdick
    [J]. Psychopharmacology, 2014, 231 : 481 - 488
  • [34] Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response
    Murrough, James W.
    Wan, Le-Ben
    Iacoviello, Brian
    Collins, Katherine A.
    Solon, Carly
    Glicksberg, Benjamin
    Perez, Andrew M.
    Mathew, Sanjay J.
    Charney, Dennis S.
    Iosifescu, Dan V.
    Burdick, Katherine E.
    [J]. PSYCHOPHARMACOLOGY, 2014, 231 (03) : 481 - 488
  • [35] Residual Depressive Symptoms in Treatment-Resistant Bipolar Depression Following Short-Term Ketamine Administration
    Pastuszak, Michal
    Cubala, Wieslaw Jerzy
    Kwasny, Aleksander
    [J]. DRUGS-REAL WORLD OUTCOMES, 2024,
  • [36] Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre, Roger S.
    Lipsitz, Orly
    Lui, Leanna M. W.
    Rodrigues, Nelson B.
    Lee, Yena
    Ho, Roger C.
    Subramaniapillai, Mehala
    Gill, Hartej
    Cha, Danielle S.
    Lin, Kangguang
    Teopiz, Kayla M.
    Nasri, Flora
    Mansur, Rodrigo B.
    Kratiuk, Kevin
    Rosenblat, Joshua D.
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2021, 292 : 714 - 719
  • [37] Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study
    Wilkowska, Alina
    Wlodarczyk, Adam
    Galuszko-Wegielnik, Maria
    Wiglusz, Mariusz S.
    Cubala, Wieslaw J.
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 2637 - 2646
  • [38] Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report
    Elkrief, Laurent
    Payette, Olivier
    Foucault, Jean-Nicolas
    Longpre-Poirier, Christophe
    Richard, Maxime
    Desbeaumes Jodoin, Veronique
    Lesperance, Paul
    Miron, Jean-Philippe
    [J]. FRONTIERS IN PSYCHIATRY, 2022, 13
  • [39] Intravenous Ketamine Treatment for Adolescents With Treatment-Resistant Depression: Clinical Effects and Impacts on Neural Structure
    Cullen, Kathryn
    Klimes-Dougan, Bonnie
    Lim, Kelvin
    Carstedt, Patricia
    Eberly, Lynn
    Roback, Mark
    Albott, Sophia
    Amatya, Palistha
    Mueller, Bryon
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S493 - S494
  • [40] Ketamine Downregulates the Expression of Heat Shock Protein 70 in Patients With Treatment-Resistant Major Depressive Disorder
    Kadriu, Bashkim
    Farmer, Cristan
    Yuan, Peixiong
    Zarate, Carlos
    [J]. NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S243 - S244